Acadia Pharma (ACAD) Misses Q1 EPS by 3c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall St slumps as sharp tech losses put Nasdaq on course for correction
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $21.88 +1.91%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.02, $0.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $268.06 million versus the consensus estimate of $280.92 million.
GUIDANCE:
Acadia Pharma sees FY2026 revenue of $1.22-1.28 billion, versus the consensus of $1.23 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharmaceuticals (ACAD) PT Raised to $38 at RBC Capital
- Modine Manufacturing (MOD) PT Lowered to $178 at Cantor Fitzgerald
- Hudson Pacific Properties (HPP) Misses Q3 EPS by 265c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
